Insider Trading & Ownership - Meyer Colin John

Real time insider trading transaction history:

  • Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Insider Trading Transactions for Meyer Colin John
Common stock purchase or sale:
Transaction
Date
Reported
DateTime
CompanySymbolInsider
Relationship
Shares
Traded
Average
Price
Total
Amount
Shares
Owned
Filing
2023-08-15
Sale
2023-08-17
4:40 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
2,740$169$463,05281,633
(Direct)
View
2023-05-15
Sale
2023-05-17
4:34 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
6,233$84.56$527,06378,373
(Direct)
View
2023-03-07
Sale
2023-03-08
5:04 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
621$84.57$52,51884,606
(Direct)
View
2023-03-02
Sale
2023-03-06
5:04 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
93,922$86.72$8,145,224322,471
(Direct)
View
2021-06-14
Sale
2021-06-16
4:04 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
60,000$142.58$8,554,906532,419
(Direct)
View
2020-11-16
Sale
2020-11-18
4:19 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
25,000$169.57$4,239,148519,783
(Direct)
View
2020-11-09
Sale
2020-11-10
5:59 pm
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
25,000$175$4,375,00072,000
(Direct)
View

Stock options: Exercise, Award, Grant, Conversion
Transaction
Date
Reported
DateTime
Exercisable
Expiration
CompanySymnbolInsider
Relationship
Shares
Traded
Conversion
Price
Shares
Owned
Filing
2023-09-26
Disposition
2023-09-26
4:30 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
649,112$00
(Direct)
View
2023-07-06
Option Award
2023-07-10
4:45 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
6,000$084,373
(Direct)
View
2023-03-02
Conversion
2023-03-06
5:04 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
88,636$0322,471
(Direct)
View
2023-03-02
Exercise
2023-03-06
5:04 pm
N/A
2026-05-25
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
88,636$0322,471
(Direct)
View
2023-03-02
Exercise
2023-03-06
5:04 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
88,636$11322,471
(Direct)
View
2023-02-28
Option Award
2023-03-01
4:18 pm
N/A
2032-01-03
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
45,000$0120,513
(Direct)
View
2023-01-03
Option Award
2023-01-04
5:01 pm
N/A
2033-01-03
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Innovation Officer
118,988$0170,988
(Direct)
View
2022-01-03
Option Award
2022-01-05
4:08 pm
N/A
2032-01-03
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
105,000$0122,000
(Direct)
View
2021-06-14
Conversion
2021-06-16
4:04 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
5,000$0532,419
(Direct)
View
2021-06-16
Exercise
2021-06-16
4:04 pm
N/A
2023-06-15
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
19,525$0532,419
(Direct)
View
2021-06-16
Exercise
2021-06-16
4:04 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
19,525$11.62532,419
(Direct)
View
2021-01-04
Option Award
2021-01-06
4:40 pm
N/A
2031-01-04
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
24,000$024,000
(Direct)
View
2020-11-16
Conversion
2020-11-18
4:19 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
25,000$0519,783
(Direct)
View
2020-11-16
Exercise
2020-11-18
4:19 pm
N/A
2026-05-25
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
25,000$0519,783
(Direct)
View
2020-11-16
Exercise
2020-11-18
4:19 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Research Officer
25,000$11519,783
(Direct)
View
2020-01-02
Option Award
2020-01-06
3:00 pm
N/A
2030-01-02
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Medical Officer
25,000$025,000
(Direct)
View
2019-12-16
Conversion
2019-12-17
5:21 pm
N/A
N/A
REATA PHARMACEUTICALS INCRETAMeyer Colin John
Chief Medical Officer
69,828$0156,779
(Direct)
View